HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

Results suggest new hope for patients with refractory chronic lymphocytic leukemia Data to support BLA submission

BARCELONA, SPAIN, June 12 ---ILEXTM Oncology, Inc. (NASDAQ: ILXO) and LeukoSite, Inc. (NASDAQ: LKST) today announced final results from an international, multi-center, pivotal Phase II clinical trial of CAMPATHR for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who are refractory to fludarabine. Results of the trial were presented this weekend at the 4th Congress of the European Haematology Association (EHA) by Michael J. Keating, MB, BS, of the M.D. Anderson Cancer Center, one of the trial's principal investigators and an internationally recognized expert in CLL. The companies plan to submit a Biologics License Application (BLA) based largely on these results later this year.

"The results of this trial are encouraging," said Dr. Keating, Associate Head for Clinical Research and Professor of Medicine and internist for the Department of Leukemia at M.D. Anderson Cancer Center. "The data suggest that CAMPATH may provide an important new treatment option for fludarabine-refractory patients, a group for whom the prognosis has, to date, been extremely poor. While the treatment of patients with leukemia has relied on chemotherapeutic agents, the use of monoclonal antibodies is an innovative approach to circumventing the disease's mechanisms for resistance."

The non-comparative trial, involved 93 previously treated patients who had received prior alkylating agents and failed fludarabine therapy (median of three prior treatment regimens). For these patients, the median life expectancy is usually six to nine months.

In the trial, patients participating at the 20 clinical sites in the United States and Europe received 30 mg of CAMPATH on an outpatient basis, as an intravenous infusion, three times a week, for four to 12 weeks. The dose was gradually escalated over the first week to 30 mg, in or
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/22/2017)... del Rey, CA (PRWEB) , ... August 22, ... ... of revenue cycle management (RCM) solutions, announced recently the availability of a new ... HIM community in appreciation for their service to the healthcare industry. E/M coding ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection ... travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ordained ... was inspired as a very young child when her older sisters studied High School ...
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins Privis ... Member for t4 Leadership Development & Consulting. He has spent his career focusing ... physician leadership development, servant leadership, data driven process improvement, and supportive technology. These ...
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that provides online ... with physicians and advanced practitioners like nurse practitioners and physician assistants ... through November of this year. The online career fairs will allow job seekers to ...
(Date:8/21/2017)... CA (PRWEB) , ... August 21, 2017 , ... FCPX ... Studios. Editors can quickly and easily add washed color grades to footage. A ... The LUT changes every pixel’s color to the corresponding color indicated by the table. ...
Breaking Medicine News(10 mins):
(Date:8/11/2017)... CAESAREA, Israel , Aug. 11, 2017 ... company with mobile health and big data solutions, today ... results on Monday, August 14 and host a conference ... second quarter 2017 operating and financial results and its ... call will be hosted by Erez Raphael , ...
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
Breaking Medicine Technology:
Cached News: